Hypolipidemics Global Market Report 2021 Featuring Abbott Laboratories, Apotex Fermentation, Biocon, Cadila Healthcare and Chunghwa Chem Syn & Biotech


DUBLIN, December 02, 2021 - (BUSINESS WIRE) - The report "Hypolipidemis Global Market Report 2021: COVID-19 Impact and Recovery to 2030" has been added ResearchAndMarkets.com to offer.

The global hypolipidemia market is forecast to decline from $ 16.23 billion in 2020 to $ 15.94 billion in 2021, with an average annual growth rate (CAGR) of -1.8%.

The decline is mainly due to the fact that companies' production was negatively impacted by COVID-19, which had previously led to restrictive containment measures involving social distancing, remote working and the closure of commercial activities that created operational challenges.

The market is expected to reach $ 18.41 billion in 2025 at a CAGR of 3.7%.

Key players in the Hypolipidemic Drugs market are Abbott Laboratories Ltd, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited, and Chunghwa Chem Syn & Biotech Co., Ltd.

Hypolipidemic Drugs market consists of hypolipidemic drug sales and related services. This industry includes facilities that manufacture hypolipidemic drugs or agents that lower lipid and lipoprotein levels in the blood. These drugs can be used to prevent cardiovascular disease and atherosclerosis in patients with hyperlipidemia. Some of the major hypolipidemic drugs include fibric acid derivatives, bile acid binding resins, nicotinamides, and cholesterol absorption inhibitors.

The market treated by this report is segmented by product type into Cholic Acid Regulator, HMG-CoA Reductase Inhibitor, Adenylate Cyclase Inhibitor, Nicotinic Acid Drugs, and others; by application in hospitals, clinics, pharmacies, cardiovasology.

Changes in people's diet and lifestyle are driving the growth of the hypolipidemic drug market. The increase in the consumption of unhealthy foods, the increasing prevalence of smoking and drinking have all led to an increase in the cholesterol intake of the population. High blood pressure contributed to nearly 1.47 million deaths in India, according to a 2019 study by Global Burden of Disease (GBD). The rise in cholesterol due to the change in people's lifestyle increases the demand for hypolipidemic drugs as they help in lowering cholesterol.

The story goes on

Companies in this market are increasingly investing in the use of data from wearables in clinical studies in order to improve the speed and efficiency of studies and thereby reduce overall costs. By continuously collecting patient data through wearable technologies, clinical trial sponsors can potentially reduce the burden of frequent site visits, which could improve patient dropout rates and the overall efficiency of clinical trials.

The use of wearables helps meet the challenge of patient recruitment, helps monitor patients, provides accurate real-time data and enables earlier decisions while the patient is in a clinical trial. Pharmaceutical companies like Sanofi and Pfizer have already invested in wearable technologies to treat hypolipidemia.

The increase in the use of biologicals acts as a major obstacle hindering the growth of the hypolipidemic drug market. Biologics are obtained from living organisms such as humans, animals and microorganisms, as opposed to chemical drugs or chemically synthesized drugs.

The increasing preference for hypolipidemic biological drugs due to side effects in the use of chemically synthesized drugs has resulted in a decline in sales of traditional hypolipidemic chemical drugs and thus hinders the growth of the hypolipidemic (chemical) drug market.

According to Harvard Medical School, 10 to 29% of people who consume hypolipidemic drugs, such as cholesterol-lowering statins, experience muscle aches and pains. For example, PCSK9 inhibitors have been used since 2015 to lower LDL cholesterol. Amgens' Repatha, a hypolipidemic biological drug, has received FDA approval for the treatment of hypolipidemia.

The approval of the hypolipidemic drugs by the EU authorities takes 6 to 12 months. Additionally, all parts of the registration dossier must be submitted together, unlike the US FDA which accepts phased filings. The US FDA will evaluate each technical section in 6 months, which can be extended to an additional 6 months if questions / concerns are raised.

However, the assessment of the technical sections is done at the same time and therefore manufacturers should identify the time-consuming steps and plan the work accordingly and indicate an anticipated approval date. In addition, the validity of the license and the extension of the application in the EU region place a burden on the manufacturer and increase the existing regulatory burden.

Therefore, hypolipidemia drug manufacturers should plan well and communicate effectively in order to minimize costs and shorten lead times.

Key topics covered:

1. Summary

2. Market characteristics for hypolipidemic drugs

3. Hypolipidemic Drugs Market Trends and Strategies

4. Effects of COVID-19 on Hypolipidemic Drugs

5. Hypolipidemia Drugs Market Size and Growth

5.1. Global Historic Hypolipidemic Drugs Market, 2015-2020, $ Billion

5.1.1. Driver of the market

5.1.2. Restrictions in the market

5.2. Global Hypolipidemic Drugs Prediction Market, 2020-2025F, 2030F, Billion US Dollars

5.2.1. Driver of the market

5.2.2. Restrictions in the market

6. Hypolipidemic Drugs Market Segmentation

6.1. Global Hypolipidemic Drugs Market, Segmentation by Product Type, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

6.2. Global Hypolipidemic Drugs Market, Segmentation By Application, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

  • hospital

  • Clinics

  • pharmacy

  • Cardiovasology

7. Regional and country analysis of the market for hypolipidemic drugs

7.1. Global Hypolipidemic Drugs Market Split by Region, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

7.2. Global Hypolipidemic Drugs Market Split by Country, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

Mentioned companies

  • Abbott Laboratories Limited

  • Apotex Fermentation Inc.

  • Biocon Limited

  • Cadila Healthcare Limited

  • Chunghwa Chem Syn & Biotech Co. GmbH.

  • Concord Biotech Limited

  • Croda Europe Limited Leeks

  • Daiichi Sankyo Company Limited

  • Dr. Reddy's Laboratories Ltd

  • DSM Sinochem Pharma India

  • Hikal

  • Ipca laboratories

  • Lek Pharmaceuticals dd

  • Lupine Limited

  • Merck Sharp & Dohme BV

  • Mylan NV

  • Nexchem Pharmaceutical Co. Ltd. CN

  • Olon SpA

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Zhejiang Jiangbei Pharma Co. Ltd. CN.

  • Moehs Iberica SL ES

  • Pfizer Inc

  • Recordati SpA IT Milano

  • AstraZeneca

  • Amgen

  • Daiichi Sankyo

  • Kowa Company Ltd.

  • Sanofi

  • Novartis

Please visit https://www.researchandmarkets.com/r/rtjik0 for more information on this report

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005532/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For EST office hours, call 1-917-300-0470
For US / CAN toll free call 1-800-526-8630
For GMT office hours, call + 353-1-416-8900. at


continue reading https://dailytechnonewsllc.com/hypolipidemics-global-market-report-2021-featuring-abbott-laboratories-apotex-fermentation-biocon-cadila-healthcare-and-chunghwa-chem-syn-biotech/?feed_id=3121&_unique_id=61b75bd423266

Commentaires

Enregistrer un commentaire

Posts les plus consultés de ce blog

Futuristic 'Green' Fabric That Works Like a Smartphone Unveiled by Scientists

Image
A new substance developed by a team of Chinese scientists that works like a smartphone could have applications in communication, navigation, healthcare, and security. SWNS The high-tech garment could improve safety for cyclists, drivers and emergency services. For example, the brush on a sleeve could instantly display a “fabric card” on its arm. The inexpensive material turns a jacket into a touchscreen - and according to the SWNS news agency, it could be in stores by Christmas. Powered by solar energy, it combines conductive and luminescent fibers with cotton. Wearable technology has been promised for years, but creating large displays that are built into functional systems has proven difficult. Researchers at Fudan University in Shanghai spectacularly tackled this problem with a display fabric nearly 20 feet long and 10 inches wide. CONNECTED : Processors in tech wearables like Fitbits could be replaced by mushroom mycelium SWNS through Fudan University The author
Lire la suite

Verizon Media unveils future-proofing strategies on tech stack and immersive experiences

Image
For the first time, Verizon Media, a division of Verizon (NYSE, Nasdaq: VZ), broadcast the Verizon Media APAC Growth Summit live on Yahoo TV across Asia. This event brought international speakers closer to Asia through virtual, immersive technology. The power of the full-tech stack and immersive technology was the focus of the two-day summit. Really connected. Global collaboration. Rico Chan, Head of APAC Sales at Verizon Media, said under the motto “Maximize Today, Accelerate Tomorrow”: “With advanced virtual event technology, we have brought together speakers from around the world to share their insights at the two-day APAC Growth Summit was streamed live with subtitles to Hong Kong and Singapore from March 23-24, and to Taiwan and Japan from March 30-31. We have seen overwhelming responses from the industry across the region eager to discover digital trends and behaviors in the post-new normal era. " The future of programmatic: Future-proof business thro
Lire la suite

TN school funding: Memphians want more money for special education, more

Image
Holding back the tears, Teresa Short described her struggles trying to help her son, a preschooler in need of special education, catch up after the school disruptions caused by COVID. Her school district, Fayette County Schools in Somerville, could only offer summer academic programs to children in K-12, she said. The reason, she was told, was the limited funding. "So I had to find private schools to try to get him to and pay out of my pocket to try and get him an education and get him where he needs to be," said Short. Given the opportunity to weigh how Tennessee should approach its first revision of the school funding formula in 30 years, Short advocated giving more money to schools overall and ensuring more money is allocated to special education students. She joined a crowded room with parents, students, educators, boards of directors, school board members and activists Thursday at the National Civil Rights Museum in Memphis to visit the second of eight town ha
Lire la suite